Nabriva Therapeutics (NASDAQ:NBRV) Earns Hold Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRVGet Rating) in a research report issued on Saturday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Nabriva Therapeutics Stock Performance

NBRV opened at $0.16 on Friday. The company has a current ratio of 2.81, a quick ratio of 2.01 and a debt-to-equity ratio of 0.01. The company’s fifty day moving average price is $0.19 and its two-hundred day moving average price is $0.28. Nabriva Therapeutics has a 1-year low of $0.16 and a 1-year high of $1.40. The company has a market cap of $108.80 million, a price-to-earnings ratio of -0.20 and a beta of 1.49.

Nabriva Therapeutics (NASDAQ:NBRVGet Rating) last released its quarterly earnings data on Wednesday, August 3rd. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.02. Nabriva Therapeutics had a negative net margin of 131.91% and a negative return on equity of 95.18%. The firm had revenue of $9.19 million for the quarter, compared to the consensus estimate of $8.53 million. On average, analysts expect that Nabriva Therapeutics will post -0.68 EPS for the current fiscal year.

Hedge Funds Weigh In On Nabriva Therapeutics

Several institutional investors have recently added to or reduced their stakes in NBRV. Renaissance Technologies LLC lifted its holdings in Nabriva Therapeutics by 102.1% during the second quarter. Renaissance Technologies LLC now owns 795,938 shares of the biotechnology company’s stock valued at $145,000 after purchasing an additional 402,144 shares during the last quarter. Frazier Life Sciences Management L.P. purchased a new stake in Nabriva Therapeutics during the first quarter valued at about $179,000. Finally, GSA Capital Partners LLP purchased a new stake in Nabriva Therapeutics during the fourth quarter valued at about $214,000. Institutional investors own 0.53% of the company’s stock.

Nabriva Therapeutics Company Profile

(Get Rating)

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia.

Recommended Stories

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.